Allarity Therapeutics, Inc. (ALLR): debt financing — Allarity Therapeutics issues $440K convertible note to 3i, LP; amends Series A conversion price to $0.405

Allarity Therapeutics, Inc.

Second closing of $440K principal senior convertible note purchased for $400K (10% original issue discount), due February 2025.
Note carries 8% annual interest, convertible at $0.405 per share; Purchaser limited to 4.99% beneficial ownership cap.
Limited Waiver Agreement permits second closing before the 30-day waiting period required by the original purchase agreement.
Conversion price of Series A Preferred Stock amended from $0.4476 to $0.405 via Sixth Certificate of Amendment filed with Delaware.
Net proceeds to be used for accounts payable and working capital; negative covenants restrict additional indebtedness over $250K.

item 1.01 item 2.03 item 3.02 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing 2025-02-13.

Instrument: convertible notes
Principal: $440,000
Counterparty: 3i, LP
Rate: 8% per annum
Maturity: 2025-02-13
Event: incurrence

Exact text from the filing

we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on February 13, 2025

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Allarity Therapeutics, Inc.: Amended Series A Preferred Stock conversion price from $0.4476 to $0.405 via Sixth Certificate of Amendment (effective 2024-02-13).

Change: charter amendment
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, we filed the Sixth Amendment to change the “Conversion Price” from $0.4476 to $0.405.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Allarity Therapeutics, Inc. entered into Limited Waiver Agreement and Second Convertible Promissory Note with 3i, LP valued at $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share (effective 2024-02-13).

Action: entry
Agreement: credit facility
Counterparty: 3i, LP
Value: $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024 (the “Second Closing”), the Parties entered into a Limited Waiver Agreement (the “Waiver Agreement”) and agreed that the Second Closing can be consummated prior to the 30 th calendar day following January 18, 2024.

View on SEC.gov

299 debt financings filed in the last 30 days. Browse all debt financings →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-013668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.